NanoViricides, Inc. NNVC
1.38 USD -0.04 (-2.82%)
At closeNov 12, 2026, 4:00 AM EST
1.29 -0.09 -6.52%
Pre-market · Nov 12, 4:00 AM ET
1.37 Day range 1.47
0.85 52-week range 1.93
- YTD
- +22.12%
- 1 year
- -8.00%
News
benzinga.com NanoViricides Advances NV-387 Measles Treatment Toward Clinical Trials Amid Rising Global Outbreaks / NanoViricides, Inc., a publicly traded company (NYSE:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic…
benzinga.com NanoViricides Announces That NV-387 Successfully Demonstrated Strong Safety, Tolerability, And Toxicological Parameters In An Animal Model Study Involving Juvenile Mouse Pups This study is expected to pave the way for pediatric use of NV-387 in clinical trials in children possibly as young as 1 year old. Pediatric drugs for Ebola, Mpox, and Measles, as well as RSV - to…
benzinga.com NanoViricides Says Its Phase IIA Ebola Treatment Clinical Trial Of NV-387 Oral Gummies Is Progressing Well The Phase IIA part of the clinical trial is designed to evaluate different dosage regimens of the oral gummies for the treatment of different severity levels of the Ebola Bundibugyo virus infection…